Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection
Table 3
The biochemical response of DAAs treatment.
All (n = 54)
CHC (n = 39)
CIR (n = 15)
Statistics
ALT0 (IU/L)
91.6 ± 68.0
99.6 ± 75.6
70.0 ± 35.1
1.841
0.072
Baseline ALT abnormality
36 (66.7%)
26 (66.7%)
10 (66.7%)
0.000
1.000
ALT normality
W4
44 (81.5%)
35 (89.7%)
9 (60.0%)
4.533
0.033
W12
49 (90.7%)
36 (92.3%)
13 (86.7%)
0.014
0.907
EOT
48 (88.9%)
36 (92.3%)
12 (80.0%)
0.649
0.420
F12
47 (87.0%)
37 (94.9%)
10 (66.7%)
5.343
0.021
TBil0 (μmol/L)
13.8 ± 7.4
11.2 ± 4.6
20.3 ± 9.4
3.306
0.005
ΔTB4_0
1.1 ± 5.0
1.1 ± 4.6
1.3 ± 5.9
0.154
0.878
ΔTB12_0
−0.6 ± 6.1
−0.4 ± 4.2
−1.1 ± 9.2
0.238
0.815
ΔTB_EOT_0
−1.4 ± 4.5
−1.3 ± 3.6
−1.9 ± 6.2
0.334
0.743
ΔTB_F12_0
−2.4 ± 6.6
−3.4 ± 5.0
0.2 ± 9.5
1.124
0.285
eGFR0 (ml/min.1.73 m2)
107.3 ± 19.0
107.0 ± 21.8
108.3 ± 9.8
0.162
0.872
ΔeGFR4_0
2.4 ± 11.1
4.6 ± 12.8
−2.2 ± 4.7
1.445
0.163
ΔeGFR12_0
0.5 ± 11.3
1.6 ± 12.8
−1.9 ± 7.1
0.903
0.372
ΔeGFR_EOT_0
2.3 ± 11.9
2.8 ± 13.6
1.3 ± 7.1
0.324
0.748
ΔeGFR_F12_0
0.0 ± 12.4
−0.8 ± 13.9
1.6 ± 8.9
0.503
0.618
CHC: chronic hepatitis C; CIR: cirrhosis; BMI: body mass index; ALT: alanine aminotransferase; TBil: total bilirubin; eGFR: estimated glomerular filtration rate; W4: week 4 of treatment; W12: week 12 of treatment; EOT: end of treatment; F12: 12 weeks after end of treatment; ALT0: ALT at baseline (same for TBil0 and eGFR0); ΔTB4_0 or ΔeGFR4_0: changes of TBil or eGFR from baseline to week 4 (TB4–TB0, or eGFR4–eGFR0); ΔTB12_0 or ΔeGFR12_0: changes of TBil or eGFR from baseline to week 12; ΔTB_EOT_0 or ΔeGFR_EOT_0: changes of TBil or eGFR from baseline to end of treatment; ΔTB_F12_0 or ΔeGFR_F12_0: changes of TBil or eGFR from baseline to 12 weeks after end of treatment.
